D.A. Davidson & CO. Acquires 3,981 Shares of Perrigo Company plc $PRGO

D.A. Davidson & CO. grew its holdings in Perrigo Company plc (NYSE:PRGO) by 6.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,717 shares of the company’s stock after acquiring an additional 3,981 shares during the period. D.A. Davidson & CO.’s holdings in Perrigo were worth $1,649,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. State of Michigan Retirement System raised its stake in shares of Perrigo by 1.2% in the first quarter. State of Michigan Retirement System now owns 32,658 shares of the company’s stock worth $916,000 after buying an additional 400 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in Perrigo by 54.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock worth $32,000 after acquiring an additional 424 shares during the period. State of Alaska Department of Revenue raised its stake in Perrigo by 2.8% during the 1st quarter. State of Alaska Department of Revenue now owns 15,984 shares of the company’s stock worth $448,000 after acquiring an additional 430 shares during the period. Amundi raised its position in shares of Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares during the period. Finally, Public Employees Retirement System of Ohio raised its position in shares of Perrigo by 1.4% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 42,290 shares of the company’s stock valued at $1,130,000 after purchasing an additional 564 shares during the period. 95.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PRGO shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Perrigo in a research report on Saturday. JPMorgan Chase & Co. reduced their price target on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Canaccord Genuity Group reduced their price target on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Finally, Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a report on Sunday. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $34.00.

Perrigo Price Performance

Shares of PRGO stock opened at $21.48 on Monday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.32 and a quick ratio of 1.24. The company has a market capitalization of $2.95 billion, a P/E ratio of -37.03 and a beta of 0.43. The company’s 50-day simple moving average is $22.26 and its two-hundred day simple moving average is $24.82. Perrigo Company plc has a one year low of $20.51 and a one year high of $30.93.

Perrigo (NYSE:PRGO) last issued its earnings results on Wednesday, August 6th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by ($0.02). Perrigo had a positive return on equity of 9.09% and a negative net margin of 1.86%.The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the company earned $0.53 earnings per share. The firm’s revenue was down .9% on a year-over-year basis. As a group, equities analysts anticipate that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 29th were given a dividend of $0.29 per share. The ex-dividend date of this dividend was Friday, August 29th. This represents a $1.16 dividend on an annualized basis and a yield of 5.4%. Perrigo’s dividend payout ratio (DPR) is presently -200.00%.

Insider Activity

In other news, Director Geoffrey M. Parker bought 4,375 shares of the stock in a transaction on Monday, August 18th. The stock was bought at an average cost of $22.97 per share, for a total transaction of $100,493.75. Following the completion of the purchase, the director directly owned 33,287 shares in the company, valued at approximately $764,602.39. The trade was a 15.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Abigail Lennox bought 1,255 shares of the stock in a transaction on Monday, September 8th. The stock was purchased at an average price of $22.41 per share, with a total value of $28,124.55. Following the completion of the purchase, the executive vice president owned 1,255 shares of the company’s stock, valued at $28,124.55. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 10,118 shares of company stock valued at $232,699 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.